Table 1.
Patient demographics and clinicopathologic characteristics in the primary cohort.
| Demographic or characteristic | PES cohort n = 106 (100%) |
Non-PES cohort n = 74 (100%) |
X2/t | P-value |
|---|---|---|---|---|
| Age, years | 57.29 ± 9.84 | 59.20 ± 10.20 | − 1.262 | 0.209 |
| Sex, N(%) | 1.247 | 0.264 | ||
| Male | 96 (90.5%) | 63 (85.1%) | ||
| Female | 10 (9.5%) | 11 (14.9%) | ||
| BMI, kg/m2 | 22.36 ± 3.04 | 22.45 ± 3.074 | − 0.192 | 0.848 |
| ECOG | 9.249 | < 0.001 | ||
| 0–1 | 59 (55.7%) | 62 (83.8%) | ||
| 2 | 47 (44.3%) | 12 (16.2%) | ||
| Liver cirrhosis | 0.054 | 0.861 | ||
| No | 52 (49.1%) | 35 (47.3%) | ||
| Yes | 54 (50.9%) | 39 (52.7%) | ||
| Child–Pugh class | 0.088 | 0.767 | ||
| A | 90 (84.9%) | 64 (86.5%) | ||
| B | 16 (15.1%) | 10 (13.5%) | ||
| BCLC staging | 3.286 | 0.070 | ||
| B | 78 (73.6%) | 45 (60.8%) | ||
| C | 28 (26.4%) | 29 (39.2%) | ||
| TACE types | 4.167 | 0.041 | ||
| C-TACE | 51 (47.2%) | 47 (63.5%) | ||
| D-TACE | 55 (51.8%) | 27 (36.5%) | ||
| Embolization degree | 20.481 | < 0.001 | ||
| Incomplete | 30 (28.3%) | 46 (62.2%) | ||
| Complete | 76 (71.7%) | 28 (37.8%) | ||
| Tumor number, n | 6.353 | 0.042 | ||
| 1 | 40 (37.7%) | 41 (55.4%) | ||
| 2–4 | 57 (53.8%) | 26 (35.1%) | ||
| ≥ 5 | 9 (8.5%) | 7 (9.5%) | ||
| Tumor diameter, cm | 7.30 ± 3.94 | 8.50 ± 4.18 | − 1.952 | 0.052 |
| Chemotherapeutic drugs | 0.319 | 0.572 | ||
| Single drug | 14 (13.2%) | 12 (16.2%) | ||
| Multiple drug | 92 (86.8%) | 62 (83.8%) | ||
| Operation time, min | 87.13 ± 30.42 | 80.72 ± 24.95 | 1.493 | 0.137 |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group.